Description
Commencement of trading in Rights Entitlements (REs) for DR LALCHANDANI LABS LIMITED from February 04, 2026 to February 17, 2026.
Summary
BSE has announced the commencement of trading in Rights Entitlements (REs) for DR LALCHANDANI LABS LIMITED. The REs will be available for renunciation trading from February 04, 2026 to February 17, 2026, with the Rights Issue opening from February 04, 2026 to February 20, 2026.
Key Points
- Trading in Rights Entitlements (REs) commences on Wednesday, February 04, 2026
- Scrip Code: 751078, Scrip ID: DLCL-RE, ISIN: INE871Z20013
- Market Lot: 4000 shares
- Group: R
- Settlement: T+1 Rolling Settlement on trade-for-trade basis
- REs tradable in dematerialized form only
- Unsubscribed or unrenounced REs will lapse after Issue Closing Date
Regulatory Changes
No regulatory changes announced. This circular provides operational details for an upcoming rights issue.
Compliance Requirements
- Trading Members must inform all clients about the commencement of trading in REs, including the specific ISIN (INE871Z20013)
- Trading Members must include a prominent disclaimer in contract notes/bills containing purchase of REs
- Disclaimer must inform clients that: (a) Purchase of REs only gives the right to participate in the Rights Issue by making an application with requisite money or to renounce the REs before issue closes, (b) REs which are neither subscribed nor renounced will lapse and be extinguished after the Issue Closing Date
- Trading Members must ensure clients do not mistake REs for ordinary shares of the company
- Trading Members should refer to notice no. 20200305-21 dated March 05, 2020 and notice no. 20200518-34 dated May 18, 2020 for additional details
Important Dates
- Renunciation Trading Period: February 04, 2026 to February 17, 2026
- Rights Issue Period: February 04, 2026 to February 20, 2026
- Issue Opening Date: February 04, 2026
- Issue Closing Date: February 20, 2026
Impact Assessment
Impact on Shareholders: Medium impact for existing shareholders of DR LALCHANDANI LABS LIMITED who need to decide whether to subscribe to the rights issue, renounce their entitlements in the market, or allow them to lapse.
Trading Impact: The two-week renunciation trading window provides liquidity for shareholders who do not wish to participate in the rights issue. The trade-for-trade settlement mechanism ensures transparent price discovery.
Operational Impact: Trading Members must update their systems to handle REs trading, ensure proper client communication, and implement mandatory disclaimers in contract notes for RE transactions.
Impact Justification
Affects shareholders of DR LALCHANDANI LABS LIMITED who wish to trade or renounce their rights entitlements during the rights issue period